article · Applied Organometallic Chemistry
A novel copper (II) complex incorporating a mono basic azo naringenin ligand has been synthesised and structurally characterised using analytical, magnetic, and spectroscopic methods alongside powder X-ray diffraction. The resulting complex adopts an octahedral geometry with the formula [Cu(L)(CH3COO)(OH2)2]. Investigations into its interactions with DNA demonstrated that the copper (II) complex possesses a stronger DNA binding ability than the uncomplexed azo naringenin ligand. In addition, evaluation through a DPPH free radical-scavenging assay confirmed the antioxidant potency of the complex. Both the azo naringenin ligand and its copper (II) complex exhibited a range of biological activities, demonstrating antitumour, antifungal, and antibacterial properties.
Developing molecules that can bind DNA and neutralise free radicals is vital for discovering new therapeutic agents. Combining organic ligands such as azo naringenin with transition metals can enhance biological effectiveness. These findings provide fundamental data on metal-based compounds that could support future efforts to target tumours, bacterial infections, and fungal pathogens.
This work could eventually support the development of novel metal-based therapeutics by pharmaceutical or biotechnology drug discovery teams. However, because the results reflect early-stage laboratory synthesis and baseline in vitro screening, the compound remains distant from real-world application, requiring extensive optimisation, toxicity profiling, and clinical testing.
AI-generated from the published abstract. Always read the original work before citing.
A new copper (II) complex containing the mono basic ligand ( HL ) azo naringenin was synthesized and structurally characterized by analytical, magnetic, and various spectroscopic techniques. An octahedron geometry was proposed for the assigned molecular formula [Cu(L)(CH 3 COO)(OH 2 ) 2 ]. Processing of powder X‐ray diffraction data for the copper (II) complex in question by the Expo 2014 computer program confirmed the proposed structure inferred from the spectroscopic studies. The DNA binding ability of the free ligand and its copper (II) complex was tested, and the results obtained demonstrated the stronger DNA binding ability of the copper (II) complex over the azo naringenin ligand. The antioxidant potency of copper (II) complex was investigated via the DPPH free radical‐scavenging assay. The present azo naringenin ligand and its copper (II) complex have shown diverse biological potentials including antitumor, antifungal, and antibacterial activities.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/aoc.7460
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
